HUMIRA® (adalimumab) Receives FDA Approval to Treat Pediatric Patients Living with Moderately to Severely Active Ulcerative Colitis

Press/Media

Period	25 Feb 2021

Media coverage

Title	HUMIRA® (adalimumab) Receives FDA Approval to Treat Pediatric Patients Living with Moderately to Severely Active Ulcerative Colitis
Media name/outlet	Nasdaq
Country/Territory	United States
Date	25/02/21
URL	https://www.nasdaq.com/press-release/humirar-adalimumab-receives-fda-approval-to-treat-pediatric-patients-living-with
Persons	Marla Dubinsky